Home
About
Services
Partners
Client Portfolio
News
Contact
‘We need it now’: U.S. farm country pins hopes on China trade deal
March 6, 2019
Czech cyber watchdog says its Huawei warning took U.S. by surprise
March 6, 2019
0
Bristol-Myers tells opponents Celgene deal is ‘best path’
Published by
Muller&Green
at
March 6, 2019
Categories
RSS
Tags
Bristol-Myers Squibb urged shareholders on Wednesday to support its planned $74 billion takeover of Celgene Corp, as it faces opposition from two large investors to what could be the largest pharmaceutical deal ever.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more